NPI: 1881142461 · CALHOUN CITY, MS 38916 · Critical Access Hospital · NPI assigned 09/13/2016
Authorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
| Authorized Official | DUCKETT, GREGORY (SR VP/CORP SECRETARY) |
| Parent Organization | BAPTIST MEMORIAL HEALTH CARE CORP. |
| NPI Enumeration Date | 09/13/2016 |
Other providers sharing the same authorized official: DUCKETT, GREGORY
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 31,369 | $1.06M |
| 2019 | 28,830 | $1.12M |
| 2020 | 26,405 | $873K |
| 2021 | 33,478 | $1.06M |
| 2022 | 43,402 | $1.08M |
| 2023 | 39,460 | $1.16M |
| 2024 | 26,625 | $919K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99284 | Emergency department visit for the evaluation and management, high severity | 8,129 | 6,348 | $1.23M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 48,334 | 3,899 | $1.23M |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 7,542 | 6,224 | $983K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 38,276 | 2,584 | $760K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3,806 | 3,066 | $683K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 4,173 | 713 | $284K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1,980 | 1,566 | $174K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4,996 | 3,335 | $169K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4,989 | 904 | $159K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4,400 | 3,533 | $152K |
| 71045 | Radiologic examination, chest; single view | 3,998 | 2,881 | $130K |
| 70450 | Computed tomography, head or brain; without contrast material | 1,574 | 1,187 | $120K |
| 71046 | Radiologic examination, chest; 2 views | 2,342 | 1,823 | $99K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1,346 | 992 | $89K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 8,182 | 1,357 | $85K |
| G0378 | Hospital observation service, per hour | 295 | 223 | $81K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 7,455 | 3,080 | $77K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,974 | 3,048 | $74K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 860 | 737 | $73K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4,197 | 3,367 | $62K |
| 80053 | Comprehensive metabolic panel | 7,087 | 5,373 | $49K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1,693 | 1,173 | $44K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1,397 | 1,190 | $43K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 8,316 | 5,778 | $38K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 218 | 186 | $34K |
| 83880 | 1,586 | 1,162 | $31K | |
| 97129 | 596 | 63 | $26K | |
| 84484 | 3,434 | 2,182 | $23K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 950 | 763 | $22K |
| 36415 | Collection of venous blood by venipuncture | 10,556 | 7,003 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 221 | 128 | $18K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 108 | 64 | $17K |
| 96361 | Intravenous infusion, hydration; each additional hour | 215 | 121 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1,221 | 1,071 | $15K |
| 97162 | 497 | 437 | $15K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 188 | 148 | $12K |
| 83605 | 2,002 | 1,330 | $10K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 161 | 155 | $10K |
| 87807 | 983 | 816 | $9K | |
| 81001 | 4,070 | 3,293 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 49 | 48 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 118 | 104 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,482 | 1,027 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 118 | 26 | $6K |
| 83735 | 1,733 | 1,184 | $6K | |
| 97116 | 688 | 136 | $6K | |
| 82553 | 444 | 363 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 454 | 374 | $4K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 133 | 25 | $4K |
| 97130 | 148 | 12 | $3K | |
| 83690 | 755 | 569 | $3K | |
| 87040 | 531 | 267 | $3K | |
| 85027 | 737 | 587 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 147 | 141 | $3K |
| 82550 | 465 | 380 | $3K | |
| 97014 | 440 | 81 | $3K | |
| 74018 | 69 | 40 | $2K | |
| A9270 | Non-covered item or service | 2,589 | 1,151 | $2K |
| 73560 | 40 | 39 | $2K | |
| 82150 | 332 | 269 | $2K | |
| 97165 | 88 | 78 | $2K | |
| 81025 | 331 | 278 | $2K | |
| 80305 | 272 | 206 | $2K | |
| 97161 | 53 | 38 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 1,376 | 878 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2,105 | 1,687 | $2K |
| 85610 | 457 | 354 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | 95 | 86 | $856.99 |
| 85730 | 124 | 110 | $688.21 | |
| 73610 | 21 | 15 | $667.80 | |
| 97535 | Self-care/home management training, each 15 minutes | 112 | 37 | $533.80 |
| 73130 | 14 | 12 | $513.28 | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 2,792 | 523 | $484.02 |
| 87086 | Culture, bacterial; quantitative colony count, urine | 109 | 98 | $481.98 |
| 96376 | 71 | 25 | $328.79 | |
| 80061 | Lipid panel | 15 | 13 | $250.44 |
| 85379 | 51 | 37 | $195.58 | |
| 80069 | 170 | 51 | $193.41 | |
| 82803 | 19 | 14 | $186.84 | |
| 86140 | 49 | 43 | $173.87 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1,059 | 725 | $130.45 |
| 82375 | 19 | 14 | $117.94 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 117 | 27 | $104.01 |
| 83050 | 19 | 14 | $70.78 | |
| 81003 | 20 | 17 | $43.91 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 22 | 13 | $30.37 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 639 | 394 | $26.55 |
| 85007 | 13 | 13 | $20.64 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 220 | 171 | $9.67 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 241 | 195 | $0.28 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 224 | 136 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 258 | 144 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 273 | 170 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 274 | 170 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 28 | 18 | $0.00 |